{"id":49,"date":"2022-11-08T08:39:38","date_gmt":"2022-11-08T08:39:38","guid":{"rendered":"https:\/\/www.ltt.co.jp\/en\/?page_id=49"},"modified":"2025-06-10T10:38:06","modified_gmt":"2025-06-10T01:38:06","slug":"history","status":"publish","type":"page","link":"https:\/\/www.ltt.co.jp\/en\/company\/history\/","title":{"rendered":"History"},"content":{"rendered":"\t\t
\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t

History of the company from its inception<\/span> to its establishment<\/span><\/h3>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t1988<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Yutaka Mizushima establishes LTT Research Institute, Inc. to support research and development of DDS (Drug Delivery System) related technologies.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
GREEN CROSS CORPORATION (currently Mitsubishi Tanabe Pharma Corporation) begins marketing a DDS formulation (liposteroid: trade name\/Rimetasone\u00ae).<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
July<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
DDS formulation (liposteroid: product name: Haloart\u00ae, Haloart\u00ae S) is launched by Taiho Pharmaceutical Co.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
October<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. begins marketing a DDS formulation (Lipo-PGE1: trade name\/PALUX\u00ae Injection)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
November<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
GREEN CROSS CORPORATION (currently Mitsubishi Tanabe Pharma Corporation) begins marketing a DDS formulation (Lipo-PGE1: trade name: Lipul\u00ae Injection).
\r\n
\r\nBegan joint research with St. Marianna University School of Medicine
\r\n
\r\nYutaka Mizushima receives the Pharmaceutical Technology Award from the Pharmaceutical Society of Japan for the invention and development of the Lipo formulation.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t1990<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
October <\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
St. Marianna University School of Medicine Research Center for Intractable Diseases is established under the leadership of Yutaka Mizushima (first director: Yutaka Mizushima)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t1992<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
KAKEN PHARMACEUTICAL CO.,LTD. launches DDS formulation (non-steroidal lipo formulation: trade name\/Ropion\u00ae).
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t1995<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Established currently Beijing Tide Pharmaceutical Co., Ltd., a joint venture with China-Japan Friendship Hospital (Beijing, China), and started the production and development of DDS (Lipo-PGE1: product name\/Kaishi) in China with technical support from TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t1997<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Began marketing a DDS formulation (Lipo-PGE1: trade name\/Kaishi) from Beijing Tide Pharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t1998<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
TAIHO PHARMACEUTICAL CO., LTD. begins marketing a DDS formulation (liposteroid: trade name\/Farnesone).
\r\n
\r\nCurrently Dainippon Sumitomo Pharma Co., Ltd. begins marketing a DDS formulation (liposteroid: brand name\/farnelate).<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2001<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Yutaka Mizushima receives the “Chinese Government Friendship Award” for the development of lipo drugs in China.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t

History of the Company from its establishment<\/span> to the present<\/span><\/h3>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2003<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
January<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
LTT Laboratories, Inc. is split off and LTT Biopharma Co., Ltd. is established to take over the pharmaceutical business.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2004<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
October<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Began marketing DDS formulation (non-steroidal lipo formulation: trade name\/Kaifeng) from Beijing Tide Pharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
November<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Listed on the Tokyo Stock Exchange Mothers
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2005<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Launch of Obagi Perfect Lift AA using our DDS technology by ROHTO Pharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
October<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\uff08\u30bd\u30fc\u30ec\u682a\u5f0f\u4f1a\u793e (wholly owned subsidiary) is established. Entered the dispensing pharmacy business.<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2006<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Phase III clinical trial of DDS formulation AS-013 completed in the U.S.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Drug Discovery Research Center, Faculty of Pharmaceutical Sciences, Kumamoto University, established under the leadership of Tohru Mizushima (Professor, Kumamoto University) (First Director: Tohru Mizushima)
\r\n
\r\nWe have established a new endowed chair (Advanced DDS) at that Center.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Concluded a joint venture agreement with Machine Parts Co., Ltd. to manufacture and sell MH-treated tableting punches.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
November<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Early phase II clinical trial of DDS formulation PC-SOD (injection) in Japan is completed. Efficacy confirmed in ulcerative colitis.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2007<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
August<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
PC-SOD license agreement for the whole of China was concluded with Beijing Tide Pharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
ASKLEPIOS Co., Ltd. becomes a wholly owned subsidiary through a share exchange
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2008<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Subsidiary ASKLEPIOS Co., Ltd. files for bankruptcy. It was excluded from the scope of consolidation.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
May<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Founder Yutaka Mizushima dies of acute heart failure
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
DDS formulation PC-SOD (injection) completes early phase II clinical trials in Japan, confirming efficacy in idiopathic interstitial pneumonia.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Tohru Mizushima becomes the second Chairman of the Board of Directors.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
October<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\u30de\u30b7\u30f3\u30d1\u30fc\u30c4\u8ca9\u58f2\uff08\u682a\uff09(wholly owned subsidiary) is established for the purpose of selling EIP products.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2009<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
February<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Head office relocated to Kaigan, Minato-ku, Tokyo (Shiodome Building)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
February<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Transferred all shares of subsidiary \u30bd\u30fc\u30ec\u682a\u5f0f\u4f1a\u793e and the company is excluded from the scope of consolidation.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Capital and business alliance agreement signed with Beijing Tide Pharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
August<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Development of PC-SOD inhalation formulation for practical use” was selected as a grant project by New Energy and Industrial Technology Development Organization (NEDO).
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Concluded a license agreement with Beijing Tide Pharmaceutical Co., Ltd. for the entire whole of China.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
December<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
PC-SOD (inhalation formulation) toxicity study for practical application development started.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2010<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
January<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Signed a joint research and development agreement with ASAHI KASEI PHARMA CORPORATION for stealth-type nanoparticles and started basic research.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
May<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Obtained composition (substance) patent for DDS formulation PC-SOD in the U.S.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
DDS formulation PC-SOD is designated as an Orphan Drug by the Ministry of Health, Labour and Welfare.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
July<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Development of stealth-type nanoparticle PGE1 formulation for practical use” was selected as a grant project by the New Energy and Technology Development Organization (NEDO).
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Started Phase I clinical trials of PC-SOD (inhalation formulation)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
November<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Signed a joint research and development agreement on stealth-type nanoparticles with Beijing Tide Pharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
December<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Phase I clinical trial of PC-SOD (inhalation formulation) in repeated dosing in healthy subjects begins.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2011<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Terminated sales activities of the Company’s EIP business
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Tohru Mizushima receives “The Pharmaceutical Society of Japan Award for the Promotion of Science” for his drug repositioning (DR) research
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Company’s stock is designated as Securities Under Supervision (as of April 1).
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
July<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Company’s shares designated as Securities to Be Delisted (as of July 8)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
July<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Concluded a license agreement with ChongKunDang Pharm.Corp (CKD) for PC-SOD (inhalation formulation) for the whole of Korea.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
August<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Delisted from the Mothers market of the Tokyo Stock Exchange (as of August 9).
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2012<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
February<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Changed capital to 100 million yen (as of February 10)
\r\n
\r\nLiquidated and excluded from consolidation\u3000\u30de\u30b7\u30f3\u30d1\u30fc\u30c4\u8ca9\u58f2
\r\n
\r\nCompleted Phase I clinical trials of PC-SOD (inhalation formulation)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
July<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Phase II international clinical trial of PC-SOD (inhalation formulation)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2013<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
July<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Tohru Mizushima receives the Nagai Award from the Japanese DDS Society for his PC-SOD research.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2014<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Completed Phase II clinical trials of PC-SOD (inhalation formulation)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2015<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
May<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Tohru Mizushima receives the KIHARA Memorial Yokohama Foundation for the Advancement of Life Sciences Applied Science Award for his drug repositioning (DR) research.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Beijing Tide Pharmaceutical Co., Ltd. approved to conduct Phase I and II clinical trials of PC-SOD in China.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
October<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Signed a license agreement with currently EA Pharma Co., Ltd. for our pipeline (LT-4004).
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2016<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Established an endowed research division (Department of Advanced Drug Discovery Science) at St. Marianna University School of Medicine
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
May<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Early Phase II clinical trials for dry eye treatment (LT-4002) begin.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2017<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Completed early phase II clinical trials for dry eye drug (LT-4002)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2018<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Signed a basic agreement with Nobelpharma Co., Ltd. for joint development of drug repositioning (DR) to expand the indications for existing drugs.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2019<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
February<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Newly established our research center in Shonan Health Innovation Park (Shonan Health Innovation Park (Shonan iPark) (Shonan Research Center)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Commenced late stage Phase II clinical trials for dry eye treatment (LT-4002)
\r\n
\r\nCommenced Phase II clinical trials (first indication) of co-development product (LT-5001) with Nobelpharma Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
November<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Commenced Phase II clinical trials (second indication) of co-development product (LT-5001) with Nobelpharma Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2020<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Signed a joint research agreement with a Japanese pharmaceutical company for the development of PC-SOD.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
August<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Completed late stage Phase II clinical trials for dry eye treatment (LT-4002)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
December<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Completed Phase II clinical trials (first indication) of a product (LT-5001) co-developed with Nobelpharma Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2021<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
January<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Commencement of tender offer by Sino Biopharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Entered into a basic capital and business alliance agreement with Sino Biopharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Concluded a consulting service agreement on DR with ASKA Pharmaceutical Holdings Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
May<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Concluded an agreement with a brokerage firm for re-listing.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Completed Phase II clinical trials (second indication) of a product (LT-5001) co-developed with Nobelpharma Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
October<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Confirmation of efficacy of co-development product (LT-5001) with Nobelpharma Co., Ltd.in Phase II clinical trials (second indication)
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2022<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
January<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Start of early Phase II clinical trials for CIPN prophylaxis (PC-SOD)\u3000with oxaliplatin
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Entered into a contract agreement with a major Japanese pharmaceutical company for the development of a DDS drug product.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Commencement of Phase III clinical trials (second indication) of a product (LT-5001) co-developed with Nobelpharma Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
December<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Signed a business alliance agreement with Sino Biopharmaceutical Co., Ltd.
\r\n<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2023<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
May<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Start of Phase III clinical trial (physician-initiated trial) for LT-5001 (indication 3) <\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
May<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Conclusion of a business consignment contract with a Japanese company aiming to expand its business in China<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Completion of Phase III clinical trial (indication 2) for LT-5001<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
July<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Completion of early Phase II clinical trials for CIPN prophylaxis (PC-SOD) with oxaliplatin<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
December<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Renewal of business alliance agreement with Sino Biopharmaceutical Co., Ltd.<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
December<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Efficacy confirmed with statistical significance in early Phase II clinical trial targeting CIPN in PC-SOD<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2024<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Donation lecture established at Sojo University Faculty of Pharmaceutical Sciences, Tohru Mizushima appointed as special professor<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
June<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Presentation of PC-SOD early Phase II Clinical Trial Results at ASCO 2024<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Start of early Phase II clinical trial for CIPN prophylaxis (PC-SOD) with paclitaxel<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
September<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
PMDA approval of Phase III clinical trial for CIPN prophylaxis (PC-SOD) with oxaliplatin<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t2025<\/span>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
January<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Confirmation of efficacy in a Phase III clinical trial (physician-initiated study) of LT-5001 for trigeminal neuralgia<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
January<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Head office relocated to Hamamatsucho (WTC annex), Minato-ku, Tokyo<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
February<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Renewal of business alliance agreement with Sino Biopharmaceutical Co., Ltd.<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
March<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Conclusion of a draft agreement (term sheet) regarding the licensing of PC-SOD in Europe<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
April<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t
Conclusion of PC-SOD joint development agreement with Alfresa Holdings Corporation<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/section>\n\n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":1693,"parent":38,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"templates\/html.php","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-49","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/pages\/49","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/comments?post=49"}],"version-history":[{"count":37,"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/pages\/49\/revisions"}],"predecessor-version":[{"id":4836,"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/pages\/49\/revisions\/4836"}],"up":[{"embeddable":true,"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/pages\/38"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/media\/1693"}],"wp:attachment":[{"href":"https:\/\/www.ltt.co.jp\/en\/wp-json\/wp\/v2\/media?parent=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}